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Tumor recurrence after surgical resection of NSCLC ob-
structs long-term disease-free survival in approximately
50% of cases. Our data suggest that combining circulating
tumor cell enumeration (as single cells or clusters) in tumor-
draining pulmonary vein and peripheral blood (assessed by
CellSearch) at the time of NSCLC surgery better identiﬁes
those patients at higher risk for lung cancer recurrence than
does peripheral circulating tumor cell number alone.
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Surgical resection of NSCLC (approximately 88%) can
produce long-term survival. However, tumor recurrence
occurs in approximately 50% of cases. Circulating tumor
cells (CTCs) are assumed to be the predominant cause of
metastatic dissemination, and evidence supports the
tumor-initiating properties of (a subset of) CTCs.1,2 The
CellSearch platform (Janssen Diagnostics LLC, Raritan, NJ)
exploits expression of cell surface epithelial markers to
capture, enrich, and enumerate CTCs. The detection of
CTCs in peripheral blood is associated with a worseprognosis in NSCLC.3,4 However, the total number of
CTCs detected by CellSearch in early-stage NSCLC is low.
Pulmonary veins drain blood directly from the lungs.
Proximity to primary tumor and blood draw upstream of
capillary bed ﬁltering implies that pulmonary vein sam-
pling may be advantageous to assess the association of
CTC prevalence with disease outcome. To test this hy-
pothesis, we performed a pilot study of CellSearch CTC
enumeration, comparing blood sampling from periph-
eral and tumor-draining pulmonary veins at the time of
tumor resection. We hypothesized that patients with
detectable pulmonary vein CTCswould have a higher risk
for disease recurrence.Methods
This was a single-center, prospective study of patients
undergoing a curative-intent operation for stage I to IIIA
NSCLC (University Hospital of South Manchester,Journal of Thoracic Oncology Vol. 11 No. 10: 1793-1797
1794 Crosbie et al Journal of Thoracic Oncology Vol. 11 No. 10Manchester, UK). Patients with a history of malignancy
within 2 years were excluded. Blood samples (10 mL)
were taken immediately before surgery from a peripheral
vein and intraoperatively (10 mL) from the cancer-
draining pulmonary vein before tumor resection or
vessel ligation to minimize artifactual elevation in CTC
number.5 CellSearch processing and analysis followed
previously published protocols.6,7 CTC enumeration was
expressed as number of cells per 7.5 mL of blood. Circu-
lating tumor microemboli (CTMs) were deﬁned as three
or more contiguous CTCs in a cluster.8
Primary and secondary outcome measures were
disease-free survival (DFS) and overall survival (OS),
respectively. Patients found to have unresectable disease
during the operation were not included in the survival
analysis. DFS and OS were measured from the day of the
operation until either the diagnosis of lung cancer
recurrence or death. In patients with no evidence of
recurrence, DFS was censored at the date of death or last
follow-up. Deaths within 30 days of the operation were
not included in the analysis. Peripheral vein CTC status
was predeﬁned as positive at one or more CTCs per 7.5
mL of blood.3 Pulmonary vein CTC status was an
exploratory end point, and high was deﬁned according to
the upper quartile of the CTC count. Kaplan-Meier curves
were used to demonstrate DFS and OS for each CTC
category and compared using log-rank tests. A Cox pro-
portional hazard regression analysis with a backward
conditional regression approach was used to deﬁne the
optimal multivariate model to determine independent
risk factors associated with DFS and OS. Log2 trans-
formation was carried out if nonlinearity was found.
The study was granted ethical approval by the North
West 7 Research Ethics Committee (reference no. 10/
H1008/79), and all participants gave written informed
consent before study participation.Results
Of the 33patientswhounderwent an operation, 30 had
a complete resection. Three patients found intra-
operatively to have unresectable disease were not
included in the analysis. The clinical parameters of the
study cohort (n ¼ 30) are detailed in Table 1. Median
study follow-up was 22.0 months (range 1–52). Lung
cancer recurrence affected 10 of 30 patients (33%), most
commonly (in seven of 10 cases) at distant sites. Almost
half of the study population died (13 of 30 patients
[43%]); one patient who diedwithin 30 days of having the
operationwas excluded. Cause of death was not recorded;
however, nine of 10patientswith recurrent disease (90%)
died compared with three of 19 (16%) patients without
disease recurrence (p ¼ 0.0002), suggesting that lung
cancer was the predominant cause.CTC and CTM Prevalence
Peripheral blood was taken from 27 of 30 patients
(90%) and a pulmonary vein sample was obtained from
the whole study cohort. CTCs (1 CTC per 7.5 mL of
blood) were more commonly detected in the pulmonary
vein (in 13 of 30 patients [43%], range 1–3093 CTCs per
7.5 mL of blood) than in the peripheral blood (in six of
27 patients [22%], range 1–4 CTCs per 7.5 mL of blood)
(p ¼ 0.018) and total CTC number was greater in the
pulmonary vein (p ¼ 0.002). Only two of 27 patients
(7%) had CTCs detected in the peripheral and pulmo-
nary vein samples; both died after lung cancer recur-
rence within 8 months of having their operation. CTMs
were detected only in pulmonary vein blood (six of 30
patients (20%), range 1–37 CTMs per 7.5 mL of blood).
The numbers of pulmonary vein CTCs and CTMs were
signiﬁcantly correlated (r ¼ 0.51, p ¼ 0.002).CTCs and Survival
Patients were stratiﬁed according to high (18 CTCs
per 7.5 mL of blood) or low (<18 CTCs per 7.5 mL of
blood) pulmonary vein CTC groups. Differences
approaching signiﬁcance in DFS (p¼ 0.055) and 3-year OS
(p ¼ 0.082) were observed (Fig. 1A and B). Clinical char-
acteristics stratiﬁed according to these groups aredetailed
in Table 1. CTMs were identiﬁed in six of seven of those in
the high-CTC group (85.7%) compared with in none of
23 of the low-CTC group (p ¼ 0.00001). The presence of
CTMs (1 CTMper 7.5mL of blood) was associatedwith a
signiﬁcant reduction in DFS (p ¼ 0.011) and OS (p ¼
0.024). The detection of any CTCs (1 CTC per 7.5 mL of
blood) in peripheral blood was associated with reduced
DFS (p ¼ 0.011) and OS (p ¼ 0.037) (Fig. 1C and D).Cox Multivariate Modeling of Survival
Variables included in the model were age, pathological
stage, and log2-transformed CTC and CTM numbers in
pulmonary and/or peripheral vein blood as continuous
variables. Both peripheral vein (p¼ 0.01) and pulmonary
vein CTC number (p ¼ 0.001) remained independent risk
factors (after Bonferroni correction) for lung cancer
recurrence along with pathological stage (p ¼ 0.00006).
The hazard ratio (HR) for lung cancer recurrence for
every doubling of CTC count was 1.51 (95% conﬁdence
interval [CI]: 1.17–1.94) for pulmonary vein and 5.26
(95% CI: 1.48–18.68) for peripheral vein CTCs. Pulmo-
nary vein CTC count (p ¼ 0.01) and pathological stage
(p ¼ 0.001) were independent risk factors for death; the
association with peripheral vein CTC number was of
borderline signiﬁcance (p ¼ 0.026) after Bonferroni
correction. The HR for death for every doubling of CTC
count was 1.33 (95% CI: 1.06–1.67) for pulmonary and
3.73 (95% CI: 1.17–11.93) for peripheral blood.
Table 1. Clinical Characteristics of the Study Population with Resectable Disease (n ¼ 30) Stratiﬁed according to Pulmonary
Vein and Peripheral Vein CTC Status
Strata All
Pulmonary Vein
CTC Status
p
Value
Peripheral Vein
CTC Status
p
ValueHigh Low Positive Negative
Total
n (%) 30 7 (23.3) 23 (76.7) — 6 (22.2) 21 (77.8) —
Age
y ± SD 67.5 ± 7.1 67.7 ± 10.6 67.5 ± 5.9 0.94 71.7 ± 8.8 65.9 ± 6.3 0.08
Male sex
n (%) 16 (53.3) 4 (57.1) 12 (52.2) 0.82 4 (66.7) 11 (52.4) 0.66
Smoking status (%)
Current 16 (53.3) 6 (85.7) 10 (43.5) 0.09 2 (33.3) 12 (57.4) 0.39
Former 14 (46.7) 1 (14.3) 13 (56.5) 4 (66.7) 9 (42.9)
Never 0 0 0 0 0
Smoking (± SD)
Age started 15.2 ± 2.5 14.3 ± 1.4 15.5 ± 2.7 0.26 15.3 ± 1.9 15.1 ± 2.7 0.85
Cigs/d 23.2 ± 12.9 23.3 ± 12.2 23.2 ± 13.4 0.99 16.6 ± 10.1 25.4 ± 14.0 0.21
Duration 43.8 ± 12.8 51.1 ± 10.7 41.5 ± 12.7 0.08 45.5 ± 14.3 41.7 ± 12.5 0.53
Pack-years 51.8 ± 36.4 60.5 ± 32.9 48.8 ± 37.8 0.47 38.7 ± 29.3 54.6 ± 40.5 0.42
FEV1 (± SD)
Liters 1.91 ± 0.72 1.96 ± 0.42 1.89 ± 0.79 0.84 1.99 ± 0.83 1.82 ± 0.70 0.62
%pred 73.4 ± 20.3 79.0 ± 20.5 71.9 ± 20.5 0.50 71.0 ± 18.0 70.4 ± 19.4 0.95
FVC (± SD)
Liters 3.09 ± 0.82 3.28 ± 0.44 3.03 ± 0.90 0.53 3.38 ± 0.96 2.91 ± 0.68 0.20
%pred 98.1 ± 17.4 104.2 ± 16.1 96.5 ± 17.8 0.39 95.7 ± 13.2 96.0 ± 17.8 0.97
FEV1/FVC
Ratio 58.8 ± 17.8 59.8 ± 9.0 58.4 ± 20.2 0.87 56.8 ± 14.5 58.6 ± 19.9 0.86
Alcohol
U/wk 16.9 ± 35.6 8.3 ± 14.2 19.6 ± 40.0 0.47 3.7 ± 8.0 15.0 ± 31.1 0.39
Pathological stage (%)
I 12 (40.0) 1 (14.3) 11 (47.8) 0.09 2 (33.3) 10 (47.6) 0.31
II 11 (36.7) 5 (71.4) 6 (26.1) 1 (16.7) 7 (33.3)
III 7 (23.3) 1 (14.3) 6 (26.1) 3 (50.0) 4 (19.0)
IV 0 0 0 0 0
Disease (%)
Squam 21 (70.0) 5 (71.4) 15 (65.2) 0.25 5 (83.3) 16 (76.2) 0.88
Adeno 8 (26.7) 1 (14.3) 7 (30.4) 1 (16.7) 4 (26.1)
Tumor size
mm ± SD 39.7 ± 29.2 45.6 ± 29.4 37.9 ± 29.6 0.55 52.5 ± 34.6 37.9 ± 28.5 0.30
PET/CT
SUV 12.0 ± 6.8 11.5 ± 5.3 12.1 ± 7.3 0.83 10.9 ± 5.1 13.0 ± 7.3 0.52
Received Adj chemo
n (%) 12 (40) 2 (28.6) 10 (43.5) 0.67 3 (50.0) 8 (38.1) 0.66
Experienced Recurrence
n (%) 10 (33.3) 4 (57.1) 6 (26.1) 0.18 4 (66.7) 5 (23.8) 0.14
Dead
n (%) 13 (44.8) 4 (57.1) 9 (40.9) 0.67 4 (66.7) 7 (35.0) 0.35
Note: For pulmonary vein circulating tumor cell status, values of 18 CTCs per 7.5 mL of blood were considered high. For peripheral vein circulating tumor cell
status, values of 1 CTCs per 7.5 mL of blood were assumed for þve values.
CTC, circulating tumor cell; Cigs, cigarettes; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; U, unit(s); Squam, squamous cell car-
cinoma; Adeno, adenocarcinoma; PET/CT, positron emission tomography/computed tomography; SUV, standardized uptake value; Adj chemo, adjuvant
chemotherapy.
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Patients were categorized in a high-risk group if they
had CTMs detected (1 CTM per 7.5 mL of blood) or two
or more CTCs per 7.5 mL of peripheral blood. These
measures were chosen to deﬁne the highest-risk groupbecause of increased speciﬁcity for lung cancer recur-
rence (in six of nine patients [66.7%]) compared with
cutoff values of one or more CTC per 7.5 mL of periph-
eral blood or 18 or more CTCs per 7.5 mL of pulmonary
vein blood (in six of 11 patients [54.5%]). Lung cancer
Figure 1. Survival in patients after curative-intent surgical resection of NSCLC. (A) Disease-free survival (DFS) and (B) 3-year
overall survival (OS) according to pulmonary vein circulating tumor cell (CTC) status. (C) DFS and (D) 3-year OS according to
peripheral vein CTC detection. (E) DFS and (F) 3-year OS stratiﬁed according to high- and low-risk CTC groups. CMT, circu-
lating tumor microemboli.
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(71.4%) compared with in ﬁve of 23 low-risk patients
(21.7%) (p ¼ 0.026). Deaths occurred in ﬁve of seven
high-risk patients (71.4%) and eight of 22 low-risk pa-
tients (36.4%) (p ¼ 0.19). Kaplan-Meier analysis
demonstrated a signiﬁcant difference in DFS (p ¼ 0.001)
and OS (p ¼ 0.002) (Fig. 1E and F). The HR for lung
cancer recurrence was 8.44 (95% CI: 2.09–34.05) (p ¼
0.003) and that for death was 7.53 (95% CI: 1.77–32.04)
(p ¼ 0.006) in the high-risk group after multivariate
analysis. Overall, these data show that pulmonary vein
CTC/CTM enumeration provides additional information
on risk for disease recurrence compared with CTC
enumeration from the peripheral circulation alone.Discussion
This study assessed the prognostic signiﬁcance of
CTCs and the feasibility of pulmonary vein sampling at
the time of surgical resection NSCLC. Signiﬁcantly more
CellSearch-enriched CTCs were detected in pulmonary
blood than in matched peripheral blood, and the pres-
ence of pulmonary vein CTCs was an independent risk
factor for lung cancer recurrence and death. CTMs were
also detected in samples of pulmonary vein blood, and
patients with detectable CTMs or two or more peripheral
vein CTCs represented a high-risk subgroup with aneightfold increased risk for disease recurrence and
sevenfold increased risk for death.
An important aspect of the study was the timing of
pulmonary vein sampling. Blood was taken before tumor
manipulation, vessel ligation, or lung resection to avoid
as much as possible artifactual elevation of CTC num-
ber.5 The association of pulmonary vein CTC count with
disease recurrence and reduced OS suggests that this
may be a biologically important cell population reﬂecting
tumor biology rather than being a consequence of sur-
gery alone. This approach was safe with no complica-
tions reported. The detection of CTMs has been reported
to increase the risk for lung cancer recurrence after
resection.3 We have previously described the prognostic
signiﬁcance in SCLC of CellSearch-detected CTMs8 and
postulate that CTMs have an increased ability to survive
in the circulation.9 In vivo models also support evidence
that CTMs have increased malignant potential.10,11
Three patients suffered disease recurrence despite
negative CTC detection by CellSearch. Coexpression of
epithelial cell adhesion molecules and cytokeratins is a
requirement for CTC capture and assignment using the
CellSearch platform. Although this subpopulation of CTCs
is biologically important as evidenced by the association
between CellSearch CTC detection and prognosis in
numerous studies,3,4,12–14 it may not provide a compre-
hensive assessment of total CTC burden. Subpopulations
October 2016 CTCs in Pulmonary Vein and NSCLC Recurrence 1797of CTCs that lose their epithelial phenotype (e.g., epithelial-
to-mesenchymal transition) may become undetectable by
CellSearch. To more fully assess CTC heterogeneity, the
use of marker-independent platforms is required; how-
ever, no other platform has been through the vigorous
validation process required for routine use in the clinic.
Conclusions and Future Directions
To conﬁrm our ﬁndings and explore the potential for
CTCs to be used in the clinical management of early-
stage NSCLC, a larger validation study is required. In
addition to the potential role of CTCs as a prognostic/
predictive biomarker, isolation and genetic analysis of
individual CTCs may shed light on tumor biology and the
metastatic process. Whether CTCs are representative of
the cells responsible for distant metastatic spread and
whether they predict the genetic landscape of recurrent
disease are important areas for future research, which
we are addressing as part of the TRACERx study.15
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